The bradykinin-challenge model successfully predicts the efficacious dose range of deucrictibant in bradykinin-mediated angioedema
Background Deucrictibant (PHA-022121) is a novel orally bioavailable bradykinin B2 receptor antagonist under development for prophylaxis and on-demand treatment of bradykinin-mediated angioedema attacks. This study aimed to assess the pharmacological effect of deucrictibant in a bradykinin-challenge model in monkeys, to determine the pharmacologically effective concentration (EC) range in a bradykinin-challenge model in humans, and to inform dose selection for clinical trials of deucrictibant in bradykinin-mediated angioedema. Methods A bradykinin-challenge model was developed in cynomolgus monkeys and applied to healthy participants. In monkeys, effects of deucrictibant on repeated bradykinin-induced transient changes in mean arterial blood pressure (MABP) were evaluated and compared with the effects of icatibant, which was used to pharmacologically validate the model. In humans, the pharmacokinetic/pharmacodynamic (PK/PD) relationship of deucrictibant was established by assessing plasma levels and deucrictibant-mediated inhibition of bradykinin-induced hemodynamic changes. Results Deucrictibant effectively inhibited bradykinin-induced changes in MABP in monkeys with a shorter time to maximal observed effect and a longer duration of effect than icatibant. In humans, single oral doses of deucrictibant (12 and 22 mg) inhibited bradykinin-induced hemodynamic changes from 1 h (first time point measured) onward. PK/PD modeling of human data estimated that plasma concentrations corresponding to the EC 50 of 2.4 ng/mL and EC 85 of 13.8 ng/mL could be maintained for at least 12 h. These parameters provided guidance for the anticipated therapeutic efficacy threshold for deucrictibant in both prophylactic and on-demand treatment of bradykinin-mediated angioedema attacks, informing the selection of dose regimens of deucrictibant for Phase 2 clinical trials. Conclusion Bradykinin-challenge studies in monkeys and humans demonstrated deucrictibant-mediated inhibition of bradykinin-induced hemodynamic changes. The results enabled selection of the Phase 2 dose regimens of deucrictibant that proved to be efficacious in prophylaxis and on-demand clinical trials in bradykinin-mediated angioedema. Clinical trial registration https://clinicaltrials.gov/study/NCT05047185 , identifier NCT05047185; RAPIDe-1: https://clinicaltrials.gov/study/NCT04618211 , identifier NCT04618211.
Authors
- Brigitte Loenders
- Peng Lü (ORCID: https://orcid.org/0009-0005-8401-4067)
- Maximilian Georg Posch (ORCID: https://orcid.org/0000-0001-8649-9129)
- Anne Lesage (ORCID: https://orcid.org/0000-0003-1958-2840)
- Jochen Knolle
- John C. Lukas
- Aleena Banerji (ORCID: https://orcid.org/0000-0001-9569-9915)
- Mónica Rodríguez (ORCID: https://orcid.org/0000-0003-0403-9810)
- Marc A. Riedl (ORCID: https://orcid.org/0000-0003-3460-1544)
- Evangelia Pardali (ORCID: https://orcid.org/0000-0002-0420-4962)
- Stephan Schmidt (ORCID: https://orcid.org/0000-0002-4998-1167)
- Markus A.K. Magerl (ORCID: https://orcid.org/0000-0001-9218-5468)
- Christoph Gibson
- Kees Groen
- Raf Crabbé
- Konrad Bork
- Juan Bravo
- Michiel Joost van Esdonk
Institutions
- University of Florida (US)
- University of California San Diego (US)
- Humboldt-Universität zu Berlin (DE)
- Clinical Trial and Consulting (US)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
- Hautklinik Heidelberg (DE)
- Mass General Brigham (US)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3389/fimmu.2026.1960471
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.00